OSI Board Rejects Astellas, Seeks Other Bids
This article was originally published in PharmAsia News
Executive Summary
OSI Pharmaceuticals told its shareholders on March 15 to reject Astellas Pharma's hostile $3.5 billion buyout offer, arguing that Astellas's bid ignores the value of OSI's cash and pipeline
You may also be interested in...
Astellas Takes Hostile $3.5 Bil. Bid To OSI Shareholders
To publicize its hostile bid for OSI Pharmaceuticals, Astellas Pharma has registered the Web site oncologyleader.com. Call it hopefulness, call it hubris, but in the race to build an oncology business, Astellas is as far back in the pack as a 14,000-person global pharmaceutical firm can be
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).